Kontafarma China reshapes board and committee structure to bolster governance

Kontafarma China Holdings Ltd ( (HK:1312) ) has shared an announcement.

Kontafarma China Holdings has reshaped its board composition effective 8 May 2026, appointing Wang Limin as chairman and president, alongside executives Ge Shouwen as vice president and Guo Zixiu as financial controller, with support from one non-executive and three independent non-executive directors. The company has also detailed memberships and leadership roles across seven board committees, clarifying oversight of audit, remuneration, nomination, risk management, share dealing and investment functions, which may strengthen corporate governance and decision-making structures for stakeholders.

Wang Limin chairs several key committees, while independent directors Tang Lai Wah, Ho Ho Ming and Yao Xiaomin take leading or member roles in audit, remuneration and risk-related bodies, balancing executive influence with independent oversight. The allocation of committee responsibilities and the provision of casting votes for committee chairs in case of tied decisions underscore Kontafarma’s emphasis on structured governance and risk control within its board operations.

More about Kontafarma China Holdings Ltd

Kontafarma China Holdings Ltd is a Cayman Islands-incorporated company listed in Hong Kong. It operates under a board structure that includes executive, non-executive and independent non-executive directors, reflecting a typical governance framework for a Hong Kong-listed enterprise.

Average Trading Volume: 1,543,117

Technical Sentiment Signal: Sell

Current Market Cap: HK$161.8M

For a thorough assessment of 1312 stock, go to TipRanks’ Stock Analysis page.